Core Viewpoint - The transformation of the former Xisanqi Building Materials City into the Jingu Life Sciences Innovation Center reflects the rapid growth and restructuring of the cell and gene therapy (CGT) industry, which is expected to reach a global market size of $30.54 billion by 2025 and $36 billion by 2030 [1][2]. Group 1: Industry Growth and Trends - The CGT industry is reshaping the healthcare sector at an astonishing pace, with significant investment opportunities identified in the upcoming years [1]. - Beijing's "14th Five-Year Plan" aims to develop the biomedicine sector into a trillion-yuan industry cluster, with Haidian District prioritizing it as a strategic emerging industry [1]. Group 2: Challenges in the Industry - The industry faces a bottleneck due to the lack of specialized spaces for CGT companies, which need various facilities such as laboratories, pilot workshops, and cold chain storage [2]. - The dispersed resource layout in Beijing's core areas increases collaboration costs among companies, hindering the release of new productive forces [2]. Group 3: Innovative Solutions - The Zhongguancun Xisanqi (Jingu) Science Park is addressing these challenges through a "urban renewal + industrial collaboration" approach, transforming old manufacturing spaces into standardized facilities for biopharmaceutical research [2]. - The Jingu Life Sciences Innovation Center, part of the Zhongguancun Xisanqi Science Park, has a building area of 53,000 square meters and is equipped to create ISO5 cleanrooms, facilitating a collaborative ecosystem for the biomedicine industry [3]. - The park has established a "collaborative matrix" by integrating various resources, including trial production facilities and medical resources from nearby hospitals, to accelerate the transformation of research outcomes [3].